Ashley Chan

A focus on her passion for leukemia research and genuine care for her patients enabled Wendy Stock, MD, to rise above—one step at a time—as a mentor, leader, and pioneer.

Sacituzumab tirumotecan plus pembrolizumab is currently being evaluated for select patients with TNBC in the phase 3 TroFuse-012 trial.

Breast cancer experts vote on their most anticipated abstracts on social media ahead of the 2025 ESMO Congress.

Early objective responses have been shown with JNJ-1900 plus immune checkpoint inhibitors for recurrent/metastatic HNSCC.

Significantly longer recurrence-free survival has been demonstrated with neoadjuvant daromun vs surgery alone in patients with locally advanced melanoma.

Experts in the gynecologic cancer landscape highlight their most anticipated presentations ahead of the 2025 ESMO Congress.

Higher response rates were shown with second-line ropeginterferon alfa-2b compared with anagrelide in patients with high-risk essential thrombocythemia.

Although clinical trials are considered a “gold standard” in identifying the efficacy of treatments, real-world data help address unmet needs in colorectal cancer.

Utidelone injection has received orphan drug designation by the FDA for the treatment of patients with pancreatic cancer.

Scott T. Tagawa, MD, MS, FACP, FASCO, discusses the evolving role of radioligand therapies for the treatment of PSMA-positive prostate cancer.

Treatment with pacritinib in a real-world clinical setting led to hemoglobin responses in 44% of patients with myelofibrosis and anemia.

Vimseltinib earned approval from the European Commission for the treatment of symptomatic, unresectable tenosynovial giant cell tumors.

John P. Diaz, MD, discusses the role of minimally invasive surgical approaches for the treatment of patients with uterine cancer.

The novel ADC CRB-701 was granted FDA fast track designation for the treatment of patients with recurrent or metastatic pretreated HNSCC.

Paolo Ghia, MD, PhD, details the final analysis of the phase 2 CAPTIVATE study evaluating frontline ibrutinib/venetoclax in patients with CLL.

Ryan M. Kahn, MD, MHS, FACOG, discusses the evolution of surgical techniques and practice-changing treatments in the ovarian cancer treatment paradigm.

Supriya Gupta, MD, discussed the utility of axi-cel and liso-cel in real-world settings as second-line treatment in large B-cell lymphoma.

Real-world data showed that lutetium Lu 177 dotatate led to partial responses in patients with metastatic bronchopulmonary neuroendocrine tumors.

The FDA approved selumetinib granules and capsules for the treatment of pediatric patients at least 1 year of age with NF1 and plexiform neurofibromas.

Dordaviprone was included as a category 2A single agent in the NCCN guidelines for recurrent or progressive H3K27M-mutant diffuse high-grade glioma.

Tepotinib showed superior outcomes in patients with adenocarcinoma MET exon 14 skipping NSCLC vs those with non-adenocarcinoma.

Ivonescimab plus chemotherapy showed significant and clinically meaningful PFS in EGFR-mutated NSCLC following progression on a third-generation TKI.

The combination of ziftomenib and cytarabine/daunorubicin showed a manageable safety profile with early efficacy in NPM1-mutated and KMT2A-rearranged AML.

Michelle Monje, MD, PhD, highlights early efficacy data with a GD2-directed CAR T-cell therapy for H3K27M-mutant diffuse midline gliomas.

Jad Chahoud, MD, MPH, discusses preliminary efficacy data with zanzalintinib plus nivolumab with/without relatlimab in untreated, advanced clear cell RCC.

China’s NMPA approved zongertinib tablets for unresectable, locally advanced or metastatic, previously treated NSCLC with HER2 mutations.

Neelam V. Desai, MD, discusses the role of first-line CDK4/6 inhibitors in HR-positive, HER2-negative and HER2-positive metastatic breast cancer.

As the FDA aims to reduce drug review times, the 15% tariff rate imposed on pharmaceuticals from Europe could affect drug access in the oncology space.

The FDA has agreed to review an NDA submission for gedatolisib in hormone receptor–positive/HER2-negative, PIK3CA wild-type advanced breast cancer.

C. Ola Landgren, MD, PhD, discusses the feasibility of daratumumab plus KRd as a standard of care for the management of newly diagnosed multiple myeloma.